What is the history of Chronic myelogenous leukemia (CML)?

Chronic myelogenous leukemia (CML) was first identified in 1845, marking a pivotal moment in medical history as one of the first cancers to be linked to a specific genetic abnormality. Today, Chronic myelogenous leukemia (CML) is considered a manageable condition for most patients thanks to the development of targeted therapies that revolutionized oncology.

When was Chronic myelogenous leukemia (CML) first described?

The history of Chronic myelogenous leukemia (CML) dates back to 1845, when physicians Rudolf Virchow in Germany and John Hughes Bennett in Scotland independently described the condition. Initially, it was called "splenic leukemia" because of the significant enlargement of the spleen observed in patients. It wasn't until the 1960s that the discovery of the Philadelphia chromosome—a reciprocal translocation between chromosomes 9 and 22—provided the definitive genetic marker for Chronic myelogenous leukemia (CML).

How has our understanding of Chronic myelogenous leukemia (CML) evolved?

The 20th century transformed Chronic myelogenous leukemia (CML) from a fatal diagnosis into a chronic condition. Key historical milestones include:

• 1960: Discovery of the Philadelphia chromosome, the first consistent chromosomal abnormality linked to human cancer.


• 1970s-80s: Use of Interferon-alpha became the standard, offering limited success but significant side effects.


• 2001: FDA approval of Imatinib (Gleevec), the first tyrosine kinase inhibitor (TKI), which targeted the BCR-ABL protein directly.

How did patient advocacy change the landscape?

In the early days, patients with Chronic myelogenous leukemia (CML) had few options beyond chemotherapy or bone marrow transplants. The rise of patient advocacy groups in the late 1990s and early 2000s played a crucial role in accelerating clinical trials for targeted therapies. Today, the DiseaseMaps.org community serves as a vital hub where 287 individuals share their experiences and navigate the complexities of long-term treatment.

Next steps

• Consult a hematologist-oncologist to discuss your specific BCR-ABL mutation status.


• Join the 287 members on DiseaseMaps.org to connect with others living with this condition.


• Review the latest clinical trial information via the National Cancer Institute (NCI).

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Chronic Myelogenous Leukemia.


• National Cancer Institute (NCI) - CML Treatment Overview.


• American Cancer Society - History of Leukemia Treatment.


• OMIM (Online Mendelian Inheritance in Man) - #608232 (BCR-ABL1).